Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis

Using surveillance and survey data, Joseph T. Wu and colleagues assess the cost-effectiveness of routine pediatric EV71 vaccination in China.

Vyšlo v časopise: Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. PLoS Med 13(3): e32767. doi:10.1371/journal.pmed.1001975
Kategorie: Research Article


Using surveillance and survey data, Joseph T. Wu and colleagues assess the cost-effectiveness of routine pediatric EV71 vaccination in China.


1. Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin. 2011;26:221–8. doi: 10.1007/s12250-011-3195-8 21847753

2. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341:929–935. doi: 10.1056/NEJM199909233411301 10498487

3. Hosoya M, Kawasaki Y, Sato M, Honzumi K, Kato A, Hiroshima T, et al. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J. 2006;25:691–694. doi: 10.1097/01.inf.0000227959.89339.c3 16874167

4. Nguyen NT, Pham HV, Hoang CQ, Nguyen TM, Nguyen LT, Phan HC, et al. Epidemiological and clinical characteristics of children who died from hand, foot and mouth disease in Vietnam, 2011. BMC Infect Dis. 2014;14:341. doi: 10.1186/1471-2334-14-341 24942066

5. Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14:e1076–e1081. doi: 10.1016/j.ijid.2010.07.006 20952237

6. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14:308–318. doi: 10.1016/S1473-3099(13)70342-6 24485991

7. World Health Organization Western Pacific Region. Emerging disease surveillance and response—hand, foot and mouth disease (HFMD). [cited 29 Jan 2015].

8. Chinese Center for Disease Control and Prevention. National Population and Health Science Data Sharing Platform. [cited 29 Jan 2015].

9. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–1105. doi: 10.1016/S1474-4422(10)70209-X 20965438

10. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–790. doi: 10.1016/S1473-3099(10)70194-8 20961813

11. World Health Organization Western Pacific Region. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva: World Health Organization; 2011.

12. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829–837. doi: 10.1056/NEJMoa1303224 24571755

13. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–828. doi: 10.1056/NEJMoa1304923 24571754

14. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–2032. doi: 10.1016/S0140-6736(13)61049-1 23726161

15. Yu H, Yang W, Varma JK. To save children’s lives, China should adopt an initiative to speed introduction of pneumonia vaccines. Health Aff (Millwood). 2012;31:2545–2553. doi: 10.1377/hlthaff.2011.1272

16. Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, Hsiao VY, et al. Hand, foot, and mouth disease in China: modelling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016. doi: 10.1371/journal.pmed.1001958

17. The World Bank. Life expectancy at birth. [cited 29 Jan 2015].

18. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171–189. 10154656

19. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253–1258. 8849754

20. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.

21. National Bureau of Statistics of China. National data: national accounts. [cited 29 Jan 2015].

22. Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS ONE. 2012;7:e37206. doi: 10.1371/journal.pone.0037206 22662137

23. Panozzo CA, Becker-Dreps S, Pate V, Weber DJ, Jonsson Funk M, Sturmer T, et al. Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007–2010. Am J Epidemiol. 2014;179:895–909. doi: 10.1093/aje/kwu001 24578359

24. National Institute for Health and Care Excellence. The guidelines manual: assessing cost effectiveness. 2012 Nov [cited 23 Mar 2015].

25. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. York: University of York Center for Health Economics; 2015.

26. Lu Y, Dong Y, Xu Y. Cost-effectiveness analysis of 4 therapeutic schemes for children herpangina. China Pharmaceuticals. 2011;20:48–50.

27. Tang X, Li W, Wang W. Cost-minimization analysis of three therapeutic schemes for hand-foot-mouth disease. China Mod Med. 2010;33:095.

28. Yang T. Cost-effectiveness analysis of medication treatment for HFMD in children. Chin J Mod Drug Appl. 2012;6:79–80.

29. He T-F, Yang T-C, Yi B, Xu G-Z. Economic burden estimation for pandemic hand foot and mouth disease in Ningbo City, 2011. Shanghai J Prev Med. 2012;9:001.

30. Yang T-C, Yi B, He T-F, Wu Y, Ma Y, Xu G. Economic burden of hand, foot and mouth disease in Ningbo, Zhejiang. Dis Surveill. 2012;27:520–523.

31. Qin Y, Zhang J, Zhang J, Mou G, Xing Y, Liu J. Investigation on economical burden and status of health care seeking among 1398 hand-foot-mouth disease cases in Yantai. Chin J Epidemiol. 2009;30:1319–1320.

32. Gan Z-K, Jin H, Li J-X, Yao X-J, Zhou Y, Zhang X-F, et al. Disease burden of enterovirus 71 in rural central China: a community-based survey. Hum Vaccin Immunother. 2015;11:2400–2405. doi: 10.1080/21645515.2015.1059980 26158689

33. Li W, Li H, Li G-F, Hu Y-H. Survey on economic burden of hand, foot and mouth disease in Huaiyin District of Jinan City 2012. Prev Med Trib. 2014;7:484–487.

34. Liu T. Research on economic burden of disease and its determinants of hand, foot and mouth disease patients in Shandong Province. Jinan: Shandong University; 2013.

35. Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ. 2008;11:471–484. doi: 10.3111/13696990802321047 19450099

36. Lee BY, Wateska AR, Bailey RR, Tai JH, Bacon KM, Smith KJ. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine. 2010;28:7731–7736. doi: 10.1016/j.vaccine.2010.09.065 20923711

37. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760–768. doi: 10.1016/S1473-3099(11)70090-1 21621466

38. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958–966. doi: 10.1016/S1473-3099(14)70841-2 25107680

Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine

2016 Číslo 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle

Zvýšte si kvalifikáciu online z pohodlia domova

Získaná hemofilie - Povědomí o nemoci a její diagnostika
nový kurz

Eozinofilní granulomatóza s polyangiitidou
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.


Nemáte účet?  Registrujte sa